Inovio Pharmaceuticals has reported a net loss attributable to the company of $6.62m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss attributable to the company of $4.54m, or $0.04 per share, for the third quarter ended 30 September 2011.
Total revenues for third quarter of 2012 were $854,696 compared to $2.64m for the third quarter of 2011.
The company reported a net loss attributable to the company of $19.01m, or $0.14 per share, for the nine months ended 30 September 2012 compared to a net loss attributable to the company of $9.78m, or $0.08 per share, for the nine months ended 30 September 2011.
Total revenue of $2.98m was reported for the first nine months of 2012 compared to $8.16m for the first nine months of 2011.
